Article: Addressing High Throughput and High Content Challenges in Drug Discovery

Traditional cell analysis platforms or dedicated single or multiplex assay systems are generally slow, offer limited analytic capabilities mandating the used of multiple platforms for comprehensive data production to meet the growing competitive pressure of the drug discovery market.
Learn how leading researchers from Dana Farber Cancer Institute, Takeda Pharmaceuticals, Kite Pharma and LifeArc are addressing these challenges with an advanced flow cytometry platform.

Download this article to learn more.

 

 

Want to learn more or request a demo?

Click Here